Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

Documenti analoghi

• Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
  di: Kim, Youjin, et al.
  Pubblicazione: (2019)
• Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
  di: Hyera Kim, et al.
  Pubblicazione: (2020-08-01)
• The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
  di: Jung, Hyun Ae, et al.
  Pubblicazione: (2020)
• Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
  di: Ku, Bo Mi, et al.
  Pubblicazione: (2021)
• Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study
  di: Ji Eun Shin, et al.
  Pubblicazione: (2025-10-01)